Spinocerebellar ataxia type 6

From WikiMD's WELLNESSPEDIA

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's weight loss doctor NYC
Philadelphia GLP-1 weight loss and GLP-1 clinic NYC

Spinocerebellar ataxia type 6
Synonyms SCA6
Pronounce N/A
Specialty N/A
Symptoms N/A
Complications N/A
Onset Adult
Duration Chronic
Types N/A
Causes Genetic mutation in the CACNA1A gene
Risks Family history
Diagnosis Genetic testing, Neurological examination
Differential diagnosis N/A
Prevention N/A
Treatment Symptomatic treatment, Physical therapy
Medication N/A
Prognosis Progressive disease
Frequency Rare
Deaths N/A


Spinocerebellar ataxia type 6 (SCA6) is a rare, late-onset, autosomal dominant disorder, which, like other types of spinocerebellar ataxia, is characterized by dysarthria, nystagmus, and ataxia of gait, stance and the limbs due to degeneration of the cerebellum and its connections. It is distinguished by the additional feature of episodic ataxia.

Genetics[edit]

SCA6 is caused by mutations in the CACNA1A gene, which encodes the α1A subunit of the P/Q type voltage-dependent calcium channel. This channel is highly expressed in the cerebellum, particularly in the Purkinje cells, which are primarily affected in SCA6.

Symptoms[edit]

The symptoms of SCA6 can vary but typically include an unsteady gait, poor hand-eye coordination, and dysarthria. These symptoms are due to the degeneration of the cerebellum and its connections, which are responsible for coordinating movement.

Diagnosis[edit]

Diagnosis of SCA6 is based on clinical observation of symptoms, a family history of the disease, and genetic testing. Genetic testing can confirm a diagnosis by identifying the mutated CACNA1A gene.

Treatment[edit]

There is currently no cure for SCA6. Treatment is focused on managing symptoms and improving quality of life. This may include physical therapy to improve mobility and speech therapy to address dysarthria.

See also[edit]

References[edit]




Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.